Showing posts with label NNVC. Show all posts
Showing posts with label NNVC. Show all posts
Saturday, January 16, 2010
Neostem - NBS
This message didn't last on iHub NNVC - off topic. I put it here for the record. Marasco is the link between these two companies in that he is involved with monoclonal antibodies (mAbs) involved in virus and vaccine issues and NanoViricides is involved with viruses for sure and Marasco is the chairman of the Advisory Board at Neostem.
Tuesday, May 26, 2009
NanoViricides, Inc. Announces Influenza Testing Agreement for FluCide
Broadly-neutralizing Activity Against Multiple Strains to be Evaluated
* On Tuesday May 26, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide™, NanoViricides’ universal anti-influenza drug candidate. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA. It will be performed in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine, which administers the LSU-Tulane Center for Experimental Infectious Disease Research (Director, K. G. Kousoulas, PhD).
The study will initially evaluate effectiveness of nanoviricide™ drug candidates against a virulent H1N1 strain which caused a severe outbreak in 1930. This well-characterized virus is expected to be a good surrogate for the current 2009 H1N1 influenza (“swine flu”) that is in the pre-pandemic stage according to the WHO. The study will then be expanded to include other influenza subtypes that are feared to be on the horizon, such as H3N2.
“We are very pleased to have a recognized expert like Dr. Kousoulas associated with this study,” said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.
The Company has previously reported that a prior version of FluCide drug candidate was superior in its effect by a very large margin when compared to oseltamivir (Tamiflu®, Roche) in an animal study. The Company has also previously reported that the same drug candidate was highly effective in cell culture studies against two different kinds of H5N1 bird flu virus, namely Vietnam 2004 Clade I virus, and Vietnam 2006 Clade II virus. The latter is closely related to the Indonesia 2006 H5N1 virus that is currently causing human fatalities in Indonesia.
“We have significantly improved the chemistry of the anti-influenza nanoviricide, both in terms of the ligand, and in terms of the backbone polymer since those early studies,” said Anil R. Diwan, Ph.D., President of the Company, adding, “We expect the new drug candidate to be even more effective than the previous one. This improved candidate is also expected to be effective against a much broader spectrum of influenza viruses than the previous one.”
NanoViricides, Inc. believes that it is possible to design a single drug capable of attacking most if not all influenza viruses because all influenza viruses use the same cell surface receptor, called sialic acid. While sialic acid occurs in two distinct conformations, the Company believes that it has designed ligands that may be capable of mimicking both of these conformations. A nanoviricide is a cell surface mimetic, and thus is designed to trap a virus particle that is targeted by the ligand attached to the nanoviricide surface. Such trapping may be expected to lead to disassembly of the virus particle, or complete killing of the virus. This represents a substantial advance beyond immunotherapeutics, or use of antibodies to combat viral diseases.
“The NanoViricides technology appears to be very promising for treating a variety of viral diseases including influenza,” says Dr. Kousoulas. Dr. Kousoulas has been previously involved with several influenza animal studies.
About THEVAC, LLC
THEVAC, LLC is a LSU spin-of company, which has been formed to produce valuable reagents and provide sophisticated services to industry in collaboration with LSU Baton Rouge.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
Source
* On Tuesday May 26, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide™, NanoViricides’ universal anti-influenza drug candidate. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA. It will be performed in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine, which administers the LSU-Tulane Center for Experimental Infectious Disease Research (Director, K. G. Kousoulas, PhD).
The study will initially evaluate effectiveness of nanoviricide™ drug candidates against a virulent H1N1 strain which caused a severe outbreak in 1930. This well-characterized virus is expected to be a good surrogate for the current 2009 H1N1 influenza (“swine flu”) that is in the pre-pandemic stage according to the WHO. The study will then be expanded to include other influenza subtypes that are feared to be on the horizon, such as H3N2.
“We are very pleased to have a recognized expert like Dr. Kousoulas associated with this study,” said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc.
The Company has previously reported that a prior version of FluCide drug candidate was superior in its effect by a very large margin when compared to oseltamivir (Tamiflu®, Roche) in an animal study. The Company has also previously reported that the same drug candidate was highly effective in cell culture studies against two different kinds of H5N1 bird flu virus, namely Vietnam 2004 Clade I virus, and Vietnam 2006 Clade II virus. The latter is closely related to the Indonesia 2006 H5N1 virus that is currently causing human fatalities in Indonesia.
“We have significantly improved the chemistry of the anti-influenza nanoviricide, both in terms of the ligand, and in terms of the backbone polymer since those early studies,” said Anil R. Diwan, Ph.D., President of the Company, adding, “We expect the new drug candidate to be even more effective than the previous one. This improved candidate is also expected to be effective against a much broader spectrum of influenza viruses than the previous one.”
NanoViricides, Inc. believes that it is possible to design a single drug capable of attacking most if not all influenza viruses because all influenza viruses use the same cell surface receptor, called sialic acid. While sialic acid occurs in two distinct conformations, the Company believes that it has designed ligands that may be capable of mimicking both of these conformations. A nanoviricide is a cell surface mimetic, and thus is designed to trap a virus particle that is targeted by the ligand attached to the nanoviricide surface. Such trapping may be expected to lead to disassembly of the virus particle, or complete killing of the virus. This represents a substantial advance beyond immunotherapeutics, or use of antibodies to combat viral diseases.
“The NanoViricides technology appears to be very promising for treating a variety of viral diseases including influenza,” says Dr. Kousoulas. Dr. Kousoulas has been previously involved with several influenza animal studies.
About THEVAC, LLC
THEVAC, LLC is a LSU spin-of company, which has been formed to produce valuable reagents and provide sophisticated services to industry in collaboration with LSU Baton Rouge.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Contact:
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
Source
Thursday, May 14, 2009
Common virus may cause high blood pressure: study
Thu May 14, 2009 8:04pm EDT
By Julie Steenhuysen
CHICAGO (Reuters) - A common virus may be a major cause of high blood pressure, researchers said on Thursday in a finding that may bring new approach to treating a condition that affects an estimated 1 billion people worldwide.
Based on a series of studies in mice, they said cytomegalovirus or CMV -- a herpes virus that affects some 60 to 99 percent of adults globally -- appears to increase inflammation in blood vessels, causing high blood pressure.
And when combined with a fatty diet, CMV may also cause hardening of the arteries, a major risk factor for heart attacks, strokes, and kidney disease, they said.
"I think it could be very important," said Dr. Clyde Crumpacker of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, who worked on the study in the Public Library of Science Journal PLoS Pathogens.
"It may suggest a whole new way of looking at high blood pressure and vascular disease," Crumpacker said in a telephone interview.
He said the research offers the first direct proof that the virus causes persistent infection in blood vessels. Doctors typically use generic drugs such as beta blockers and ACE inhibitors to control blood pressure, a condition that affects one in every three adults in the United States.
Crumpacker said the study suggests vaccines and antiviral drugs may offer a new approach at treating hypertension.
Currently, there is no vaccine, but several companies, including Sanofi-Aventis, Novartis , GlaxoSmithKline PLC and Vical, are working on them.
And Swiss drugmaker Roche Holding AG makes an antiviral drug called Valcyte to prevent CMV infections in transplant recipients.
CMV AND DIET
By age 40, most adults will have been exposed to CMV, although many never experience any symptoms. But the virus can cause harm in people with compromised immune systems, such as transplant recipients, and it is a major cause of birth defects in babies whose mothers were infected during pregnancy.
In one experiment, Crumpacker and colleagues examined four groups of lab mice. Two were fed a standard diet and two were fed a high fat diet. After for weeks, half of the mice from the standard and fatty diet groups were exposed to the virus.
Six weeks later, mice in both infected groups had elevated blood pressure, but 30 percent of infected mice on high cholesterol diet also showed signs of atherosclerosis.
"This strongly suggests that the CMV infection and the high cholesterol diet might be working together," Crumpacker said.
In another study of kidney cells in infected mice, the team found high levels of the enzyme renin, which is known to cause high blood pressure. They found the same high rates of the enzyme in human blood vessel cells infected with CMV.
And they found that CMV infection increased markers for inflammation in blood vessels.
More research is needed looking at the role of viruses in causing heart disease, but Crumpacker said the findings suggest new treatment possibilities.
"Some cases of hypertension might be treated or prevented by antiviral therapy or a vaccine against CMV," he said.
http://www.reuters.com/article/healthNews/idUSTRE54E00E20090515
Cancer, MS, high blood pressure - what else will viruses be shown to cause! And NNVC's Cides will cure them all. Eh? That should be good for a nickel rise tomorrow. VVBG.
By Julie Steenhuysen
CHICAGO (Reuters) - A common virus may be a major cause of high blood pressure, researchers said on Thursday in a finding that may bring new approach to treating a condition that affects an estimated 1 billion people worldwide.
Based on a series of studies in mice, they said cytomegalovirus or CMV -- a herpes virus that affects some 60 to 99 percent of adults globally -- appears to increase inflammation in blood vessels, causing high blood pressure.
And when combined with a fatty diet, CMV may also cause hardening of the arteries, a major risk factor for heart attacks, strokes, and kidney disease, they said.
"I think it could be very important," said Dr. Clyde Crumpacker of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, who worked on the study in the Public Library of Science Journal PLoS Pathogens.
"It may suggest a whole new way of looking at high blood pressure and vascular disease," Crumpacker said in a telephone interview.
He said the research offers the first direct proof that the virus causes persistent infection in blood vessels. Doctors typically use generic drugs such as beta blockers and ACE inhibitors to control blood pressure, a condition that affects one in every three adults in the United States.
Crumpacker said the study suggests vaccines and antiviral drugs may offer a new approach at treating hypertension.
Currently, there is no vaccine, but several companies, including Sanofi-Aventis, Novartis , GlaxoSmithKline PLC and Vical, are working on them.
And Swiss drugmaker Roche Holding AG makes an antiviral drug called Valcyte to prevent CMV infections in transplant recipients.
CMV AND DIET
By age 40, most adults will have been exposed to CMV, although many never experience any symptoms. But the virus can cause harm in people with compromised immune systems, such as transplant recipients, and it is a major cause of birth defects in babies whose mothers were infected during pregnancy.
In one experiment, Crumpacker and colleagues examined four groups of lab mice. Two were fed a standard diet and two were fed a high fat diet. After for weeks, half of the mice from the standard and fatty diet groups were exposed to the virus.
Six weeks later, mice in both infected groups had elevated blood pressure, but 30 percent of infected mice on high cholesterol diet also showed signs of atherosclerosis.
"This strongly suggests that the CMV infection and the high cholesterol diet might be working together," Crumpacker said.
In another study of kidney cells in infected mice, the team found high levels of the enzyme renin, which is known to cause high blood pressure. They found the same high rates of the enzyme in human blood vessel cells infected with CMV.
And they found that CMV infection increased markers for inflammation in blood vessels.
More research is needed looking at the role of viruses in causing heart disease, but Crumpacker said the findings suggest new treatment possibilities.
"Some cases of hypertension might be treated or prevented by antiviral therapy or a vaccine against CMV," he said.
http://www.reuters.com/article/healthNews/idUSTRE54E00E20090515
Cancer, MS, high blood pressure - what else will viruses be shown to cause! And NNVC's Cides will cure them all. Eh? That should be good for a nickel rise tomorrow. VVBG.
Thursday, April 30, 2009
Why aren’t new therapies for treating swine flu (and other diseases?) available?
Nano Chem Report
Blogging on nanomedicine, dendrimers and nanolaw since January 2009
A few years ago, I had the pleasure of meeting Anil Diwan, the founder of Nanoviricides at a conference. He’d developed some interesting technology for drug delivery and had formed a company to commercialize it: Nanoviricides (www.nanoviricides.com). I found the technology compelling enough to even buy some stock in the company, but the commercialization process is clearly long and hard. Blogging on nanomedicine, dendrimers and nanolaw since January 2009
What they’ve developed is termed a nanoviricide, which consists of two components. The first component is a ligand designed to bind specifically to a target surface. These ligands can be altered to bind to a variety of different viruses. The second component is a polymer nanoparticle. Once the ligand binds to the virus, the polymer then flows around the virus. This effectively “slimes” the virus, and inactivates it. The energetics of causing the polymer to flow around the virus are probably driven by entropy, but I’m not sure it’s been well studied/modeled. The advantage of this technology over a lot of competing technologies is that the ligand has to only bind to the virus- the actual binding site isn’t that critical. In contrast, most drugs designed to interfere with viruses do so by blocking the entry of the virus into a cell or by attacking the virus in a specific fashion – such as replication. Most AIDS drugs work this way. Unfortunately, these drugs can fail because the virus uses a variety of ways to gain entry into a cell- hence the need for things like an AIDS cocktail. What this means is that it’s not enough for most drugs to just bind to the surface of the virus- they have to get to the right spot on the virus to be effective. Nanoviricides compound is different since the purpose of the ligand is merely to recognize a virus and bind to it- the polymer does the rest. It’s a much more tractable problem.
Why would it be nice to have such a drug to be widely available? Well, the vaccine approach has proven to be very effective at controlling many of the infectious diseases that used to take an enormous toll on human life such as smallpox, polio, rubella, etc. Unfortunately, there are some diseases such as AIDS where it’s been very hard to develop a vaccine, even after decades of effort. The other problem is that vaccines generally don’t do a lot if you’ve already been infected with the disease. Once you’ve been infected, generally the infection has to run its course.
Most therapeutic approaches utilize the body’s immune system in some fashion. The nanoviricide is actually a very different approach since it really operates largely independently of normal immune processes by providing an additional way to inactivate viruses. Even people with compromised immune systems should be able to tolerate a nanoviricide, and once a virus has been “slimed” it’s eventually recognized as a foreign body and excreted.
A nanoviricide for swine flu would be pretty useful about now. It would be a good second line of defense for people who weren’t vaccinated for whatever reason. Some vaccines are not well tolerated in the general population and it may not be practical to vaccinate the entire population. If there would be a reasonable alternative therapy to a vaccine, the risks of not being vaccinated are much more acceptable. While a nanoviricide would not confer long lasting immunity from the disease, since the outbreaks of swine flu are so rare, this may not be a significant drawback. It would certainly reduce the mortality of the disease and likely lower the costs of treatment by shortening the time course of the illness and the amount of supportive care necessary.
It’s generally government entities that purchase vaccines, but this process has been a troubled endeavor as of late. While it’s clear that the Obama administration has lots on its plate right now, a better treatment for people who do get infected with swine flu would certainly reduce some public anxiety. It’s probably too late to manufacture a nanoviricide in quantity to have an effect on this outbreak of swine flu, but it should be possible to have something in hand for the next one.
Sam Brauer
Nanotech Plus, LLC
(203) 968-8899
Source
Wednesday, April 29, 2009
Dr. Henry Niman talks Swine Flu
VIDEO
Niman - We are at Level 6, in effect - the WHO going to 4 from 3 is equivalent to going from 3 to 6. So we are up to our necks in it. Will the summer ahead be like 1918 and mild with few deaths? Probably. Will our deaths occur in the fall like in 1918? Could be - that was the 1918 model.
For my part - will NNVC have any part at all, large or small, in ameliorating this catastrophe at hand?? From what I've heard so far I have my doubts.
NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu
Already shown to be effective against diverse influenza subtypes such as H1N1 and different clades of H5N1
On Monday April 27, 2009, 7:00 am EDT
Source
Niman - We are at Level 6, in effect - the WHO going to 4 from 3 is equivalent to going from 3 to 6. So we are up to our necks in it. Will the summer ahead be like 1918 and mild with few deaths? Probably. Will our deaths occur in the fall like in 1918? Could be - that was the 1918 model.
For my part - will NNVC have any part at all, large or small, in ameliorating this catastrophe at hand?? From what I've heard so far I have my doubts.
NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu
Already shown to be effective against diverse influenza subtypes such as H1N1 and different clades of H5N1
On Monday April 27, 2009, 7:00 am EDT
Source
Tuesday, April 21, 2009
Tuesday, February 3, 2009
NexBio
NexBio - another possible company cohort for NanoViricides:
Fludase® (DAS181) is a broad-spectrum drug candidate for the prophylaxis and treatment of respiratory infections by all types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as all types of parainfluenza virus. Fludase® is currently in phase I clinical development, and has successfully completed its First-In-Man trial.
MECHANISM OF ACTION: FLUDASE® BLOCKS IFV ENTRY INTO CELLS
Fludase® is a recombinant fusion protein (see figure 1) that inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and other viruses such as parainfluenza from both infecting the human body and amplifying in already-infected individuals.
In the human respiratory tract, cell-surface sialic acids act are the host cell receptors for all influenza A and B and parainfluenza viruses. Fludase® works by inactivating these sialic receptors in the airway epithelium, therefore preventing viral entry into cells.
Source
Finally, I would like to express my gratitude for the support of the National Institutes of Health and the National Institute of Allergy and Infectious Disease, without which our critical research would not be possible.
Mang Yu
CEO
Source
NexBio is a five-year-old biotechnology company located in San Diego, California, founded to create and commercialize novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human disease. All funding to date has been from the National Institutes of Health in the form of grants and contracts, totaling ~$63 million.
Source
Source
Contract for $49.8M to support Fludase(R) development, all from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Source
United States Patent Application 20050004020
Kind Code A1
Yu, Mang ; et al. January 6, 2005
Broad spectrum anti-viral therapeutics and prophylaxis
Abstract
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as a virus. Preferred target cells are epithelial cells. The invention provides compositions and methods for preventing viral diseases, such as influenza, using compounds having anchoring domains that can bind target cells linked to enzymatic activities that can act extracellularly to interfere with viral infection of target cells. The invention also provides compositions and methods for preventing viral diseases such as influenza using compounds having anchoring domains that can bind target cells linked to protease inhibitors that can act extracellularly to interfere with viral infection of target cells.
Source
United States Patent Application 20050112751
Kind Code A1
Fang, Fang ; et al. May 26, 2005
Novel class of therapeutic protein based molecules
Abstract
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
Source
2 results found in the Worldwide database for:
NexBio as the applicant
(Results are sorted by date of upload in database)
1 TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES in my patents list
Inventor: MALAKHOV MICHAEL [US] ; FANG FANG [US] Applicant: NEXBIO INC [US] ; MALAKHOV MICHAEL [US] (+1)
EC: IPC:
Publication info: WO2009015286 (A2) — 2009-01-29
2 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES in my patents list
Inventor: MALAKHOV MICHAEL P [US] ; FANG FANG [US] Applicant: NEXBIO INC [US]
EC: A61K9/14; A61K9/00M20B; (+9) IPC: A61K9/16; A61K38/16; A61K38/48; (+3)
Publication info: KR20080090525 (A) — 2008-10-08
Source
Refs:
WIPO
WO/2009/015286
WO/2007/114881
Fludase® (DAS181) is a broad-spectrum drug candidate for the prophylaxis and treatment of respiratory infections by all types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as all types of parainfluenza virus. Fludase® is currently in phase I clinical development, and has successfully completed its First-In-Man trial.
MECHANISM OF ACTION: FLUDASE® BLOCKS IFV ENTRY INTO CELLS
Fludase® is a recombinant fusion protein (see figure 1) that inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and other viruses such as parainfluenza from both infecting the human body and amplifying in already-infected individuals.
In the human respiratory tract, cell-surface sialic acids act are the host cell receptors for all influenza A and B and parainfluenza viruses. Fludase® works by inactivating these sialic receptors in the airway epithelium, therefore preventing viral entry into cells.
Source
Finally, I would like to express my gratitude for the support of the National Institutes of Health and the National Institute of Allergy and Infectious Disease, without which our critical research would not be possible.
Mang Yu
CEO
Source
NexBio is a five-year-old biotechnology company located in San Diego, California, founded to create and commercialize novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human disease. All funding to date has been from the National Institutes of Health in the form of grants and contracts, totaling ~$63 million.
Source
- NexBio lives off grants, year after year, $63 Million in 5 years, so far.
- I note that NexBio uses the sialic acid stuff in their virus fighting efforts. They block the virus from attaching to the cell it is targeting by interfering with the sialic acid attachment points on cells. They block those attachment points with a covering chemical so the virus has no way to attach to the cell it seeks. I think they do their thing on the cells themselves and do not do anything to the virus directly. NNVC does attack the virus directly and immobilizes it by making the cide look to the virus like a cell with the same sialic acid attachment points that the virus attaches to and becomes trapped unable to infect any cells themselves.
- I found this:
Source
- So...I guess NNVC targets the sialic acid binding bits on the virus (making the virus think the cide particles are the host cells by presenting sialic acid binding sites for the virus to attach to), whereas NexBio tagets the sialic acid itself on the cell that the virus is looking to bind to and covers it so the virus can't find it. Two sides of the same coin perhaps?
- Re the government giving grants:
- Wouldn't it make sense to combine the likes of NNVC and NexBio into one grant? More bang for the buck? They certainly are similar!
- Re NexBio funding:
Contract for $49.8M to support Fludase(R) development, all from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Source
- Re NexBio IP:
United States Patent Application 20050004020
Kind Code A1
Yu, Mang ; et al. January 6, 2005
Broad spectrum anti-viral therapeutics and prophylaxis
Abstract
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as a virus. Preferred target cells are epithelial cells. The invention provides compositions and methods for preventing viral diseases, such as influenza, using compounds having anchoring domains that can bind target cells linked to enzymatic activities that can act extracellularly to interfere with viral infection of target cells. The invention also provides compositions and methods for preventing viral diseases such as influenza using compounds having anchoring domains that can bind target cells linked to protease inhibitors that can act extracellularly to interfere with viral infection of target cells.
Source
United States Patent Application 20050112751
Kind Code A1
Fang, Fang ; et al. May 26, 2005
Novel class of therapeutic protein based molecules
Abstract
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
Source
2 results found in the Worldwide database for:
NexBio as the applicant
(Results are sorted by date of upload in database)
1 TECHNOLOGY FOR THE PREPARATION OF MICROPARTICLES in my patents list
Inventor: MALAKHOV MICHAEL [US] ; FANG FANG [US] Applicant: NEXBIO INC [US] ; MALAKHOV MICHAEL [US] (+1)
EC: IPC:
Publication info: WO2009015286 (A2) — 2009-01-29
2 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES in my patents list
Inventor: MALAKHOV MICHAEL P [US] ; FANG FANG [US] Applicant: NEXBIO INC [US]
EC: A61K9/14; A61K9/00M20B; (+9) IPC: A61K9/16; A61K38/16; A61K38/48; (+3)
Publication info: KR20080090525 (A) — 2008-10-08
Source
- Re relevance?
- Not sure but interesting insofar as viral infection is attacked using targeting on cells. And, more importantly, if NexBio can garner $63million in government grants for their R&D and manufacture can we be far behind?
Refs:
WIPO
WO/2009/015286
WO/2007/114881
- Note (From WO/2007/114881):
- Note as to particle sizing (From WO/2007/114881):
Thursday, January 22, 2009
SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS
(WO/2009/011702) SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS
- Biblio. Data
- Description
- Claims
- National Phase
- Notices
- Documents
| Latest bibliographic data on file with the International Bureau | ||||||||||||
| ||||||||||||
| IPC: | A61K 31/74 (2006.01) | |||||||||||
| Applicants: | ALLEXCEL, INC. [US/US]; 135 Wood Street, Suite 200, West Haven, CT 06516 (US) (All Except US). DIWAN, Anil, R. [US/US]; (US) (US Only). ONTON, Ann, Louise [US/US]; (US) (US Only). | |||||||||||
| Inventors: | DIWAN, Anil, R.; (US). ONTON, Ann, Louise; (US). | |||||||||||
| Agent: | DEMERS, James, P.; Kenyon & Kenyon LLP, One Broadway, New York, NY 10004 (US). | |||||||||||
| Title: | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS |
| Abstract: |  The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells. |
Anticancer drugs that can be encapsulated and delivered by these polymers include but are not limited to doxorubicin, camptothecin, docetaxel, paclitaxel, topotecan, irinotecan, imatinib, sunitinib, sorafenib, axitinib, pazopanib, etoposide, methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cladribine, cladribine, staurosporine, cytarabine, melphalan, leurosine, actinomycin, daunorubicin, epirubicin, idarubicin, mitomycin D, mitomycin A, carninomycin, aminopterin, tallysomycin, podophyllotoxin,
cisplatinum, carboplatin, vinblastine, vincristine, vindesin, retinoic acid, colchicine, dexamethasone, and tamoxifen, and derivatives and analogs of these drugs, as well as photodynamic agents, nucleic acids, nucleic acid analogues, and nucleic acid complexes. Nucleic acid analogues include species such as thiophosphates, phosphoramidates, and peptide nucleic acids. Nucleic acid complexes are ionic complexes of oligonucleic acids or analogues thereof with substantially charge-neutralizing amounts of cationic or polycationic species.
As a result of the ability of the polymers of the invention to encapsulate anticancer drugs, the present invention also provides pharmaceutical compositions, which comprise one or more π-polymers of the invention in combination with a therapeutically effective amount of one or more pharmacologically active anticancer agents, and a pharmaceutically acceptable carrier or excipient. Suitable carriers and excipients include water and saline, and solid additives such as buffers, salts, sugars, polysaccharides such as cellulose and derivatives thereof, and various humectants, glidants, preservatives, binding and dispersing agents known in the art. The polymers of the invention can render effective what would otherwise, in the prior art, have been an ineffective amount of an anticancer agent. For purposes of this disclosure, therefore, a "therapeutically effective amount" is the amount of agent that renders the overall composition effective.
Source
Friday, November 7, 2008
SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS
Title of Invention: SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS
(Click pic for a clearer view)
International Application No.: PCT/US2007/001607
International Filing Date: 22.01.2007
Pub. No.: WO 2008/091246
WIPO Publication Date: 31.07.2008
USPTO Details:
Link to USPTO
In the EPO:
EPO Souce
Company: NanoViricides (NNVC)
(Click pic for a clearer view)
International Application No.: PCT/US2007/001607
International Filing Date: 22.01.2007
Pub. No.: WO 2008/091246
WIPO Publication Date: 31.07.2008
USPTO Details:
| PCT/US07/01607 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS |  |
Link to USPTO
In the EPO:
SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS
| | | | | | | | | | | | | | | | | | |  |
| Bibliographic data | Description | Claims | Mosaics | Original document | INPADOC legal status | | |||||||||||||
 | | | | | | | | |  | ||||||||||
| | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company: NanoViricides (NNVC)
Subscribe to:
Posts (Atom)